Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma-Reference-Cited by-同舟云学术

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Published:2021-05 Issue:10 Volume:10 Page:3214-3223
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Iacoboni Gloria¹²³^ORCID,Villacampa Guillermo⁴,Martinez‐Cibrian Nuria⁵,Bailén Rebeca⁶⁷,Lopez Corral Lucia⁸⁹,Sanchez Jose M.¹⁰,Guerreiro Manuel¹¹,Caballero Ana Carolina¹²¹³,Mussetti Alberto¹⁴¹⁵,Sancho Juan‐Manuel¹⁶^ORCID,Hernani Rafael¹⁷¹⁸,Abrisqueta Pau¹²³,Solano Carlos¹⁷¹⁸¹⁹,Sureda Anna¹⁴¹⁵,Briones Javier¹²¹³,Martin Garcia‐Sancho Alejandro⁸⁹,Kwon Mi⁶⁷,Reguera‐Ortega Juan Luis⁵,Barba Pere¹²³^ORCID,

Affiliation:

1. Department of Hematology University Hospital Vall d'Hebron Barcelona Spain

2. Department of Medicine Universitat Autònoma de Barcelona Bellaterra Spain

3. Experimental Hematology Vall d’Hebron Institute of Oncology (VHIO) Barcelona Spain

4. Oncology Data Science Vall d’Hebron Institute of Oncology (VHIO) Barcelona Spain

5. Department of Hematology University Hospital Virgen del Rocio Sevilla Spain

6. Department of Hematology Hospital General Universitario Gregorio Marañón Madrid Spain

7. Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain

8. Hematology Department Hospital Clínico Universitario de SalamancaIBSAL, CIBERONC Salamanca Spain

9. Centro de Investigación del Cáncer‐IBMCC Salamanca Spain

10. Hematology Department Hospital 12 de Octubre Madrid Spain

11. Department of Hematology Hospital La Fe Valencia Spain

12. Hematology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain

13. Josep Carreras Leukaemia Research Institute Barcelona Spain

14. Hematology Department Institut Catala d'Oncologia Hospital Duran i Reynals, L'Hospitalet De Llobregat Spain

15. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) L'Hospitalet De Llobregat Barcelona Spain

16. Hematology Department ICO‐IJC Hospital Germans Trias i Pujol Barcelona Spain

17. Department of Hematology Hospital Clínico Universitario de Valencia Valencia Spain

18. Instituto de Investigación Sanitaria INCLIVA Valencia Spain

19. Department of Medicine University of Valencia Valencia Spain

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3881

Reference30 articles.

1. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

2. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

3. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

4. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

5. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

3. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22

4. Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma;HemaSphere;2024-08

5. A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma;Frontiers in Oncology;2024-07-18